3M (NYSE: MMM) has entered into an agreement to sell its rights to the Neoplast™ and Neobun™ brands and related assets in Thailand and certain other Southeast Asia countries, including the manufacturing assets of its Ladlumkaew, Thailand, facility to Selic Corp Public Company Limited (Selic), a company focusing on bon
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.